ACP Healthtech

What they fund

• Regulatory-Stage Medtech — Companies actively pursuing FDA or MDR clearances, requiring operational capital to navigate the final regulatory hurdles [1].
• AI-Enabled Diagnostics — B2B software and AI-driven diagnostic tools targeting high-throughput analysis and enhanced imaging capabilities [1].
• Global Scale — A mandate with operational presence across the EU, US, and Middle East, supporting companies aiming for international market access [1].
• TechBio & Robotics — Investments in automated systems for clinical applications, including robotics-powered IVF and automated histopathology platforms [1].
• De-risked Value Creation — Firms that have completed early development phases and are positioned for regulated market entry and commercial inflection [2].

Investment thesis

ACP Healthtech deploys capital-efficient growth-stage funding at regulatory inflection points, targeting de-risked value creation in B2B Healthtech, AI-Diagnostics, and Smart Medtech [1]. The firm focuses on companies navigating FDA or MDR clearance, providing operational capital and strategic support to accelerate market access [2]. The strategy connects financial returns with solutions for diseases affecting over 80% of the global population [2]. ACP targets a smaller, deeply supported portfolio rather than broad-stage investing [2]. Credibility: ACP Healthtech website and Bestes profile detail the regulatory-focused mandate and portfolio strategy [1][2].

Value add

ACP provides deep regulatory and clinical expertise to guide portfolio companies through complex FDA and MDR approval processes [2]. The firm offers strategic board-level support and operational guidance to accelerate market access and commercialization [1]. ACP connects founders with a network of Tier-1 global institutions and strategic co-investors to facilitate follow-on funding [1]. Fit verdict: Ideal for healthtech founders who have cleared early R&D but require specialized regulatory navigation and operational capital to reach market. Founder diligence script: 1. How does ACP's regulatory network specifically accelerate our MDR/FDA timeline? 2. What is the expected board involvement during the clearance phase? 3. Can you share examples of how you've helped a portfolio company navigate a specific regulatory rejection or delay? 4. How do you structure follow-on capital for companies that successfully clear regulatory hurdles?

Portfolio focus

• AI Diagnostics — 3D Ultrasound Imaging Platform utilizing AI-based enhancement compatible with existing 2D probes [1].
• Digital Pathology — Automated Histopathology Platform employing AI-enabled light-sheet microscopy for high-throughput tissue analysis [1].
• Reproductive Tech — AI- & Robotics-Powered IVF Platform featuring automated sperm selection systems to improve outcomes [1].
• Remote Monitoring — Neteera Technologies, a contactless vital signs monitoring company based in Israel [2].
• Care Technology — Lillian Care, a portfolio company focused on care technology solutions [2].

Notable investments & exits

• No Publicly Disclosed Exits — As a newly launched fund (2025), specific exits have not been publicly disclosed [2].
• Team Track Record — The founding team has overseen multiple successful exits in the healthtech and medtech space prior to ACP [1].
• Portfolio Companies — Neteera Technologies and Lillian Care are current portfolio companies, but exit outcomes are not yet public [2].
• Regulatory Milestones — The firm's focus on FDA/MDR clearances suggests potential exits upon successful market access [1].

Strategic implications

ACP's focus on regulatory inflection points creates a moat against broad-stage healthtech VCs, as few firms offer deep FDA/MDR expertise. The fund's capital-efficient model reduces dependency on large LP commitments, allowing for agile deployment in niche regulatory opportunities. A key risk is the concentration of regulatory risk; a series of FDA/MDR rejections could impact fund performance and LP confidence.

Where they could go further

ACP should expand its regulatory network to include emerging markets beyond the EU and US, such as the Middle East, to support global commercialization. The firm could enhance its value proposition by offering structured commercialization support post-clearance, bridging the gap between regulatory approval and market success. ACP should develop a clearer framework for measuring and reporting on the impact of its regulatory support, providing LPs with tangible metrics on value creation.